×
About 2,570 results

ALLMedicine™ Focal Segmental Glomerulosclerosis Center

Research & Reviews  919 results

Pediatric Kidney Transplantation
http://emedicine.medscape.com/article/1012654-overview

Jun 30th, 2022 - Practice Essentials In children and adolescents younger than 18 years, the adjusted incidence of end-stage renal disease (ESRD) in the United States in 2019 was 12 cases per million population. Over the decade from 2009 to 2019, the adjusted ESRD ...

Pediatric Kidney Transplantation
https://emedicine.medscape.com/article/1012654-overview

Jun 30th, 2022 - Practice Essentials In children and adolescents younger than 18 years, the adjusted incidence of end-stage renal disease (ESRD) in the United States in 2019 was 12 cases per million population. Over the decade from 2009 to 2019, the adjusted ESRD ...

A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases
https://clinicaltrials.gov/ct2/show/NCT02639260

Jun 24th, 2022 - Background. ManNAc (N-acetyl D-mannosamine) is an uncharged monosaccharide that is the biologic precursor of N-acetyl neuraminic acid (Neu5Ac, sialic acid). Sialic acids are the negatively charged, terminal monosaccharides of carbohydrate chains t...

Pathogenesis of Glomerulosclerosis
https://clinicaltrials.gov/ct2/show/NCT00001392

Jun 24th, 2022 - The present protocol seeks to advance our understanding of sclerosing glomerular and tubulointerstitial kidney diseases, including but not limited to variants of focal segmental glomerulosclerosis (FSGS) and chronic kidney disease of unknown etiol...

see more →

Guidelines  2 results

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
https://doi.org/10.1016/j.kint.2021.05.015
Kidney International; Rovin BH, Adler SG et. al.

Sep 25th, 2021 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (G...

Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Impr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983378
Kidney International; Swanepoel CR, Atta MG et. al.

Feb 6th, 2018 - HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulti...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  69 results

A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases
https://clinicaltrials.gov/ct2/show/NCT02639260

Jun 24th, 2022 - Background. ManNAc (N-acetyl D-mannosamine) is an uncharged monosaccharide that is the biologic precursor of N-acetyl neuraminic acid (Neu5Ac, sialic acid). Sialic acids are the negatively charged, terminal monosaccharides of carbohydrate chains t...

Pathogenesis of Glomerulosclerosis
https://clinicaltrials.gov/ct2/show/NCT00001392

Jun 24th, 2022 - The present protocol seeks to advance our understanding of sclerosing glomerular and tubulointerstitial kidney diseases, including but not limited to variants of focal segmental glomerulosclerosis (FSGS) and chronic kidney disease of unknown etiol...

Genetic Markers for Focal Segmental Glomerulosclerosis
https://clinicaltrials.gov/ct2/show/NCT00001393

Jun 24th, 2022 - Focal segmental glomerulosclerosis (FSGS) and a related condition, collapsing glomerulopathy, are chronic renal diseases affecting the glomerular podocytes. Currently, over thirteen genetic mutations are associated with FSGS. We are interested in ...

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
https://clinicaltrials.gov/ct2/show/NCT05003986

Jun 23rd, 2022 - This is a multicenter, open-label, 108-week study of sparsentan in approximately 57 pediatric subjects aged ≥1 year to <18 years with selected proteinuric glomerular diseases, divided into 2 populations, defined as follows: Population 1: Subjects ...

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
https://clinicaltrials.gov/ct2/show/NCT03493685

Jun 16th, 2022 - This is a randomized, multicenter, double-blind, parallel, active-control study. Approximately 300 patients aged 8 to 75 years (inclusive) will be enrolled in the study. The study will be conducted in approximately 300 study centers, globally. The...

see more →

News  33 results

Nephrotic Syndrome Patients at High Risk of Kidney Failure, Vascular Problems
https://www.medscape.com/viewarticle/954056

Jul 1st, 2021 - NEW YORK (Reuters Health) - Adults with primary nephrotic syndrome (NS) had close to a 20 times greater risk of developing kidney failure and higher risks of several cardiovascular diseases and death compared to those without NS in a large analysi...

Protein Predicts Risk of AKI in COVID-19 Patients
https://www.medscape.com/viewarticle/939052

Oct 13th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Admission levels of a specific protein predict the development of acute kidney injury (AKI) as well as the need for dialysis in patients hospitali...

Late-onset neutropenia more common than expected in patients on rituximab
https://www.mdedge.com/rheumatology/article/228758/lupus-connective-tissue-diseases/late-onset-neutropenia-more-common
Steve Cimino

Sep 18th, 2020 - A new study has found that late-onset neutropenia is a notably common and occasionally serious occurrence in rituximab-treated patients with autoimmune diseases. Dr.

24-year-old man • prednisone therapy for nephrotic syndrome • diffuse maculopapular rash • pruritis
https://www.mdedge.com/familymedicine/article/223501/dermatology
MDedge Family Medicine; Neil E. Soifer, MD, Michael J. Hepner, MD

Jun 8th, 2020 - THE CASE A 24-year-old man with no past medical history was referred to a nephrologist for a 5-month history of leg swelling and weight gain. His only medication was furosemide 40 mg/d, prescribed by his primary care physician.

BRIEF-Vifor Pharma: VFMCRP And Chemocentryx Announce Topline Data From Phase-II Lumina-1 Trial Of CCX140 In Focal Segmental Glomerulosclerosis
https://www.reuters.com/article/brief-vifor-pharma-vfmcrp-and-chemocentr/brief-vifor-pharma-vfmcrp-and-chemocentryx-announce-topline-data-from-phase-ii-lumina-1-trial-of-ccx140-in-focal-segmental-glomerulosclerosis-idUSASN0006W6

May 18th, 2020 - May 18 (Reuters) - VIFOR PHARMA AG: * VFMCRP AND CHEMOCENTRYX ANNOUNCE TOPLINE DATA FROM PHASE-II LUMINA-1 TRIAL OF CCX140 IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) Source text for Eikon: Further company coverage: (Gdansk Newsroom)

see more →

Patient Education  1 results see all →